Matthew R. Kane - 07 May 2021 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
President and CEO, Director
Signature
/s/ Dario Scimeca, Attorney-in-Fact for Matthew R. Kane
Issuer symbol
DTIL
Transactions as of
07 May 2021
Net transactions value
-$162,172
Form type
4
Filing time
11 May 2021, 16:27:14 UTC
Previous filing
11 Jun 2021
Next filing
14 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise $861 +21,514 +1.1% $0.0400* 1,999,732 07 May 2021 Direct
transaction DTIL Common Stock Sale $83,489 -9,742 -0.49% $8.57 1,989,990 07 May 2021 Direct F1
transaction DTIL Common Stock Options Exercise $861 +21,514 +1.1% $0.0400* 2,011,504 10 May 2021 Direct
transaction DTIL Common Stock Sale $80,404 -9,746 -0.48% $8.25 2,001,758 10 May 2021 Direct F1, F2
holding DTIL Common Stock 10,841 07 May 2021 By Spouse F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Employee Stock Option (Right to Buy) Options Exercise $0 -21,514 -33% $0.000000 43,028 07 May 2021 Common Stock 21,514 $0.0400 Direct F4
transaction DTIL Employee Stock Option (Right to Buy) Options Exercise $0 -21,514 -50% $0.000000 21,514 10 May 2021 Common Stock 21,514 $0.0400 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.31. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Shares are held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4 The option is fully vested and exercisable.